Bariatrics Clinical Trial - Celgene RPC01-3204
Bariatrics
Status:
Open (Study open and enrolling)ClinicalTrials.gov:
NCT03467958CONDITION(S): Crohn Disease - TRIAL: Celgene RPC01-3204 - This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease